Plain-English translation of NCT06863272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to treat metastatic castration-resistant prostate cancer—a serious form of prostate cancer that has spread to other parts of the body and no longer responds to standard hormone treatments. Researchers want to see if this medication works better when given by itself, or when combined with other existing cancer drugs. The study will enroll about 360 men to compare different treatment combinations.
Men with advanced prostate cancer that stops responding to hormone therapy have limited treatment options, and the medications currently available don't work for everyone. This trial exists to see whether this new treatment approach could offer better outcomes and give patients more hope.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an injection or infusion every 3 weeks, either alone or combined with other medications taken by mouth, depending on which treatment group you are assigned to. Some participants may receive treatment for up to 10 cycles (about 6 months), while others may continue longer if the treatment is working and you are tolerating it well. You will have regular clinic visits for blood work, scans, and check-ups to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States